ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
04 juin 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
23 mai 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
30 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
23 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled.The trial is on track to announce interim six-month data on...
ProQR Announces Annual Meeting of Shareholders
11 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
10 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing.As an...
ProQR to Present at Upcoming Investor Conference
05 mars 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
12 févr. 2018 07h00 HE
|
ProQR Therapeutics N.V.; Foundation Fighting Blindness
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting...
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
06 févr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
08 janv. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....